Humanized Anti-RAGE Monoclonal Antibodies for Alzheimer's Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's Disease, particularly those targeting RAGE, rely on polyclonal antibodies that are not suited for chronic human treatment due to their inefficacy in addressing the interaction between RAGE and amyloid-β peptides, leading to inadequate management of cerebral blood flow and amyloid plaque formation.
Innovation Solution
Development of novel monoclonal antibodies specifically binding to the C-domains of RAGE, such as mAb7F9, mAb11E6, and mAb4E5, which block the binding of Aβ-globulomers and neutralize the effects of Aβ1-40 on cerebral vasculature, offering high affinity and low dissociation kinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polyclonal antibodies are used to target RAGE, then they can be generated from animal serum, but they are not suited for chronic human treatment due to inefficacy in addressing the interaction between RAGE and amyloid-β peptides
Solution Approach 1:
The patent transforms polyclonal antibodies from animal serum into monoclonal antibodies with humanized or chimeric structures, changing the fundamental parameters of antibody origin, specificity, and molecular composition to achieve both efficacy and suitability for chronic human treatment
Solution Approach 2:
The patent creates monoclonal antibodies that replicate and enhance the desired function of polyclonal antibodies while eliminating their limitations, producing identical or superior binding activity against RAGE with improved therapeutic properties for long-term use
2Reliability
If existing anti-RAGE antibodies are used, then they can be generated, but they do not effectively block the binding of Aβ-globulomers to RAGE
Solution Approach 1:
The patent focuses on creating monoclonal antibodies with specific binding characteristics targeted at the RAGE-Aβ interaction site, optimizing local binding properties to achieve effective blocking capability while maintaining manageable development complexity
Solution Approach 2:
The patent employs novel monoclonal antibodies as intermediary molecules that specifically mediate the blocking of Aβ-globulomer binding to RAGE, providing a controlled and effective therapeutic intervention
3Ease of manufacture
If polyclonal antibodies from animal serum are used, then they can be produced, but they cause immune responses and are not suitable for long-term therapy
Solution Approach 1:
The patent fundamentally changes the antibody production parameters by transitioning from animal serum to humanized or chimeric monoclonal antibody systems, eliminating immuneogenicity while maintaining production feasibility
Solution Approach 2:
The patent replaces short-lived polyclonal antibodies from animal serum with stable, long-acting monoclonal antibodies that can be produced recombinantly, eliminating the need for repeated animal immunizations and reducing immune response risks
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These monoclonal antibodies effectively reduce amyloid plaque formation, improve cerebral blood flow, and protect neurons from Aβ-induced damage, providing a promising therapeutic approach for Alzheimer's Disease.
Implementation Method 1
novel monoclonal antibodies that bind to the C-domains of RAGE... high affinity and low dissociation kinetics
Implementation Method 2
block the binding of Aβ-globulomers and neutralize the effects of Aβ1-40 on cerebral vasculature
Data Source
AI summary
The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid β and advanced glycation-end-products.